Top of page
Global Site Navigation

School of Medical and Health Sciences

Local Section Navigation
You are here: Main Content

Professor Mel Ziman

Honorary Professor

Staff Member Details
Email: m.ziman@ecu.edu.au

Mel is an Honorary Professor in the School of Medical and Health Sciences having worked at ECU for many years.  Her areas of expertise include Melanoma and Huntington's disease.

Background

  • 2020-present: Honorary Professor, School of Medical and Health Sciences, ECU
  • 2013-2020: Professor, School of Medical and Health Sciences, ECU
  • 2011-2013: Associate Professor, School of Medical Sciences, ECU
  • 2005-2010: Associate Professor, School of Exercise, Biomedical and Health Science, ECU
  • 2003-2005: Senior Lecturer, School of Exercise, Biomedical and Health Science, ECU
  • 2001-2003: Lecturer, School of Exercise, Biomedical and Health Science, ECU
  • 1996-2001: Senior Research Fellowship, School of Pathology and Laboratory Medicine, UWA

Professional Associations

  • Society for Melanoma Research, USA
  • ANZMTG
  • Australian Neuroscience Society,
  • Human Genetics Society of Australia,
  • Australian Society for Medical Research
  • Australian and New Zealand Society of Development and Cell Biology
  • Combined Biological Society
  • International Society of Differentiation (ISD)

Awards and Recognition

University and National Teaching Awards

  • 2012:UniJobs Lecturer of the Year Award for the Top 10 Lecturers at ECU in 2011
  • 2012:ECU award for Excellence in Postgraduate Supervision
  • 2011:VC Excellence Award for Engagement in Research
  • 2010:  VC Citation for excellence in development of a Teaching and Research Nexus
  • 2010: Citation for Outstanding Contribution to Student Learning – Australian Learning and Teaching
  • 2008: VC Citation for excellence in development of a Teaching and Research Nexus
  • 2008: Citation for Outstanding Contribution to Student Learning – Australian Learning and Teaching Council (Carrick)
  • 2008: ECU Certificate of excellence in Learning and Teaching – UTEI over 85
  • 2005: ECU award for Excellence in Postgraduate Supervision

Other

  • 2010 - 2016: NHMRC grant review panel member
  • 2009-2015: National OLT grant review panel member
  • 2015:   WAHTN Committee Member
  • 2014:Parliamentary Standing Committee on Health - Skin cancer in Australia
  • 2013:ASPIRE Professional Development Award, Perth Convention Bureau
  • 2012-  NHMRC Research Translation Faculty Member

Research Areas and Interests

  • The role of developmental genes in the proliferation, differentiation and migration of cells in the embryo and in disease processes such as cancer including Cutaneous Malignant Melanoma and neurodegenerative diseases including Huntington’s disease.
  • Characterisation of circulating cells in Melanoma
  • Multidisciplinary therapy and neurogenesis in Huntington’s disease.

Qualifications

  • Bachelor of Science Honours, South Africa.
  • Degree of Doctor of Philosophy, South Africa, 1983.

Research Outputs

Journal Articles

  • Asante, D., Mohan, G., Acheampong, E., Ziman, M., Calapre, L., Meniawy, T., Gray, E., Beasley, A. (2023). Genetic analysis of heterogeneous subsets of circulating tumour cells from high grade serous ovarian carcinoma patients. Scientific Reports, 13(1), Article number 2552. https://doi.org/10.1038/s41598-023-29416-z.
  • Vaddi, PK., Osborne, DG., Nicklawsky, A., Williams, NK., Menon, DR., Smith, D., Mayer, J., Reid, A., Domenico, J., Nguyen, GH., Robinson, WA., Ziman, M., Gao, D., Zhai, Z., Fujita, M. (2023). Ctla4 Mrna Is Downregulated By Mir-155 In Regulatory T Cells, And Reduced Blood Ctla4 Levels Are Associated With Poor Prognosis In Metastatic Melanoma Patients. Frontiers in Immunology, 14(2023), article number 1173035. https://doi.org/10.3389/fimmu.2023.1173035.

Journal Articles

  • Marsavela, G., McEvoy, A., Pereira, M., Reid, A., Al-Ogaili, Z., Warburton, L., Khattak, A., Abed, A., Meniawy, T., Millward, M., Ziman, M., Beasley, L., Gray, E. (2022). Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression. British Journal of Cancer, 126(3), 401-408. https://doi.org/10.1038/s41416-021-01507-6.
  • Turner, K., Bartlett, D., Grainger, S., Eddy, C., Reyes, A., Kordsachia, C., Turner, M., Stout, J., Georgiou-Karistianis, N., Henry, J., Ziman, M., Cruickshank, T. (2022). Profiling Social Cognition in Premanifest Huntington's Disease. Journal of the International Neuropsychological Society, 28(3), 217-229. https://doi.org/10.1017/S1355617721000357.

Journal Articles

  • Cruickshank, T., Porter, T., Laws, S., Ziman, M., Bartlett, D. (2021). Hair and salivary cortisol and their relationship with lifestyle, mood and cognitive outcomes in premanifest Huntington’s disease. Scientific Reports, 11(December 2021), Article number 5464. https://doi.org/10.1038/s41598-021-84726-4.
  • Beasley, A., Isaacs, T., Vermeulen, T., Freeman, J., Desousa, J., Bhikoo, R., Hennessy, D., Reid, A., Chen, F., Bentel, J., McKay, D., Conway, R., Pereira, M., Mirzai, B., Beasley, L., Erber, W., Ziman, M., Gray, E. (2021). Analysis of Circulating Tumour Cells in Early-Stage Uveal Melanoma: Evaluation of Tumour Marker Expression to Increase Capture. Cancers, 13(23), Article 5990. https://doi.org/10.3390/cancers13235990.
  • Asante, D., Morici, M., Mohan, G., Acheampong, E., Spencer, I., Lin, W., Van Miert, P., Gibson, S., Beasley, A., Ziman, M., Beasley, L., Meniawy, T., Gray, E. (2021). Multi-Marker Immunofluorescent Staining and PD-L1 Detection on Circulating Tumour Cells from Ovarian Cancer Patients. Cancers, 13(24), Article number 6225. https://doi.org/10.3390/cancers13246225.
  • Reyes, A., Bartlett, D., Rankin, T., Zaenker, P., Turner, K., Teo, W., Fu, SC., Domingos, J., Georgiou-Karistianis, N., Ziman, M., Cruickshank, T. (2021). Clinical Determinants of Dual Tasking in People With Premanifest Huntington Disease. Physical Therapy, 101(4), Article number pzab016. https://doi.org/10.1093/ptj/pzab016.

Journal Articles

  • Lo, J., Reyes, A., Pulverenti, T., Rankin, T., Bartlett, D., Zaenker, P., Rowe, G., Feindel, K., Poudel, G., Georgiou-Karistianis, N., Ziman, M., Cruickshank, T. (2020). Dual tasking impairments are associated with striatal pathology in Huntington’s disease. Annals of Clinical and Translational Neurology, 7(9), 1608-1619. https://doi.org/10.1002/acn3.51142.
  • Cruickshank, T., Bartlett, D., Govus, A., Hannan, A., Teo, W., Mason, S., Lo, J., Ziman, M. (2020). The relationship between lifestyle and serum neurofilament light protein in Huntington’s disease. Brain and Behavior, 10(5), Article number e01578. https://doi.org/10.1002/brb3.1578.
  • Marsavela, G., Johansson, P., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Khattak, A., Meniawy, T., Amanuel, B., Millward, M., Hayward, N., Ziman, M., Gray, E., Beasley, L. (2020). The Prognostic Impact of Circulating Tumour DNA in Melanoma Patients Treated with Systemic Therapies-Beyond BRAF Mutant Detection. Cancers, 12(12), Article number 3793. https://doi.org/10.3390/cancers12123793.
  • Beasley, A., Bentel, J., Allcock, R., Vermeulen, T., Beasley, L., Isaacs, T., Ziman, M., Chen, F., Gray, E. (2020). Low-Pass Whole-Genome Sequencing as a Method of Determining Copy Number Variations in Uveal Melanoma Tissue Samples. The Journal of Molecular Diagnostics, 22(3), 429-434. https://doi.org/10.1016/j.jmoldx.2019.12.005.
  • Warburton, L., Meniawy, T., Beasley, L., Pereira, M., McEvoy, A., Ziman, M., Gray, E., Millward, M. (2020). Stopping targeted therapy for complete responders in advanced BRAF mutant melanoma. Scientific Reports, 10(1), Article number 18878. https://doi.org/10.1038/s41598-020-75837-5.
  • Warburton, L., Beasley, L., Pereira, M., Reid, A., Robinson, C., Amanuel, B., Ziman, M., Millward, M., Gray, E. (2020). Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression. Cancers, 12(11), Article number 3486. https://doi.org/10.3390/cancers12113486.
  • Turner, M., Reyes, A., Bartlett, D., Culpin, S., Hart, N., Hardt, L., Feindel, K., Poudel, G., Ziman, M., Cruickshank, T. (2020). Exploring the brain-body composition relationship in Huntington’s disease. The Journal of Musculoskeletal and Neuronal Interactions, 20(3), 332-338.
  • Dejong, H., Abbott, S., Zelesco, M., Spilsbury, K., Martin, L., Sanderson, R., Ziman, M., Kennedy, B., Wood, F. (2020). A novel, reliable protocol to objectively assess scar stiffness using shear wave elastography. Ultrasound in Medicine and Biology, 46(7), 1614-1629. https://doi.org/10.1016/j.ultrasmedbio.2020.03.003.
  • Clark, M., Rizos, H., Pereira, M., McEvoy, A., Marsavela, G., Beasley, L., Meehan, K., Ruhen, O., Khattak, A., Meniawy, T., Long, G., Carlino, M., Menzies, A., Millward, M., Ziman, M., Gray, E. (2020). Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget, 11(44), 4016-4027. https://doi.org/10.18632/oncotarget.27790.
  • Marsavela, G., Lee, J., Beasley, L., Wong, S., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Abed, A., Khattak, A., Meniawy, T., Dawson, S., Sandhu, S., Carlino, M., Menzies, A., Scolyer, R., Long, G., Amanuel, B., Millward, M., Ziman, M., Rizos, H., Gray, E. (2020). Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 26(22), 5926-5933. https://doi.org/10.1158/1078-0432.CCR-20-2251.
  • Aya-Bonilla, C., Morici, M., Hong, X., McEvoy, A., Sullivan, R., Freeman, J., Beasley, L., Khattak, A., Meniawy, T., Millward, M., Ziman, M., Gray, E. (2020). Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells. British Journal of Cancer, 122(7), 1059-1067. https://doi.org/10.1038/s41416-020-0750-9.
  • Khattak, A., Reid, A., Freeman, J., Pereira, M., McEvoy, A., Lo, J., Frank, M., Meniawy, T., Didan, A., Spencer, I., Amanuel, B., Millward, M., Ziman, M., Gray, E. (2020). PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study. The Oncologist, 25(3), e520-e527. https://doi.org/10.1634/theoncologist.2019-0557.
  • Khattak, A., Abed, A., Reid, A., McEvoy, A., Millward, M., Ziman, M., Gray, E. (2020). Role of Serum Vascular Endothelial Growth Factor (VEGF) as a Potential Biomarker of Response to Immune Checkpoint Inhibitor Therapy in Advanced Melanoma: Results of a Pilot Study. Frontiers in Oncology, 10(30 June 2020), Article number 1041. https://doi.org/10.3389/fonc.2020.01041.
  • Bartlett, D., Dominguez D, JF., Lazar, A., Kordsachia, C., Rankin, T., Lo, J., Govus, A., Power, B., Lampit, A., Eastwood, P., Ziman, M., Cruickshank, T. (2020). Multidisciplinary rehabilitation reduces hypothalamic grey matter volume loss in individuals with preclinical Huntington's disease: A nine-month pilot study. Journal of the Neurological Sciences, 408(15 January 2020), 116522. https://doi.org/10.1016/j.jns.2019.116522.
  • Zaenker, P., Prentice, D., Ziman, M. (2020). Tropomyosin autoantibodies associated with checkpoint inhibitor myositis. OncoImmunology, 9(1), Article number 1804703. https://doi.org/10.1080/2162402X.2020.1804703.
  • Cruickshank, T., Reyes, A., Pulverenti, T., Rankin, T., Bartlett, D., Blazevich, T., Poudel, G., Ziman, M., Trajano, G. (2020). Rate of torque development and striatal shape in individuals with prodromal Huntington's disease. Scientific Reports, 10(2020), Article number 15103. https://doi.org/10.1038/s41598-020-72042-2.
  • Dejong, H., Abbott, S., Zelesco, M., Spilsbury, K., Ziman, M., Kennedy, B., Martin, L., Wood, F. (2020). Objective quantification of burn scar stiffness using shear-wave elastography: Initial evidence of validity. Burns, 46(8), 1787-1798. https://doi.org/10.1016/j.burns.2020.05.009.
  • Bartlett, D., Govus, A., Rankin, T., Lampit, A., Feindel, K., Poudel, G., Teo, W., Lo, J., Georgiou-Karistianis, N., Ziman, M., Cruickshank, T. (2020). The effects of multidisciplinary rehabilitation on neuroimaging, biological, cognitive and motor outcomes in individuals with premanifest Huntington's disease. Journal of the Neurological Sciences, 416(15 September 2020), Article number 117022. https://doi.org/10.1016/j.jns.2020.117022.
  • Goonoo, N., Boodhun, A., Ziman, M., Gray, E., Bhaw-Luximon, A. (2020). Repurposing nano-enabled polymeric scaffolds for tumor-wound management and 3D tumor engineering. Regenerative Medicine, 15(10), 2229-2247. https://doi.org/10.2217/rme-2020-0072.
  • Asante, D., Beasley, L., Ziman, M., Meniawy, T., Gray, E. (2020). Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?. Cancer Letters, 468(1 January 2020), 59-71. https://doi.org/10.1016/j.canlet.2019.10.014.

Journal Articles

  • Phan, T., Carter, O., Waterer, G., Chung, LP., Hawkins, M., Rudd, C., Ziman, M., Strobel, N. (2019). Determinants for concomitant anxiety and depression in people living with chronic obstructive pulmonary disease. Journal of Psychosomatic Research, 120(May 2019), 60-65. https://doi.org/10.1016/j.jpsychores.2019.03.004.
  • Acheampong, E., Spencer, I., Lin, W., Ziman, M., Millward, M., Gray, E. (2019). Is the Blood an Alternative for Programmed Cell Death Ligand 1 Assessment in Non-Small Cell Lung Cancer?. Cancers, 11(7), article no. 920. https://doi.org/10.3390/cancers11070920.
  • Bartlett, D., Dominguez D, JF., Reyes, A., Zaenker, P., Feindel, K., Newton, R., Hannan, A., Slater, J., Eastwood, P., Lazar, A., Ziman, M., Cruickshank, T. (2019). Investigating the relationships between hypothalamic volume and measures of circadian rhythm and habitual sleep in premanifest Huntington's disease. Neurobiology of Sleep and Circadian Rhythms, 6(January 2019), p. 1-8. https://doi.org/10.1016/j.nbscr.2018.07.001.
  • Aya-Bonilla, C., Gray, E., Manikandan, J., Freeman, J., Zaenker, P., Reid, A., Khattak, M., Frank, M., Millward, M., Ziman, M. (2019). Immunomagnetic-Enriched Subpopulations of Melanoma Circulating Tumour Cells (CTCs) Exhibit Distinct Transcriptome Profiles. Cancers, 11(2), Article number 157. https://doi.org/10.3390/cancers11020157.
  • Gray, E., Witkowski, T., Pereira, M., Beasley, L., Herron, K., Irwin, D., Chapman, B., Khattak, A., Raleigh, J., Hatzimihalis, A., Cebon, J., Sandhu, S., McArthur, G., Millward, M., Ziman, M., Dubrovic, A., Wong, S. (2019). Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel. The Journal of Molecular Diagnostics, 21(3), 418-426. https://doi.org/10.1016/j.jmoldx.2018.12.001.
  • Beasley, L., Giardina, T., Robinson, C., Reid, A., Al-Ogaili, Z., Pereira, M., McEvoy, A., Warburton, L., Hayward, N., Khattak, A., Meniawy, T., Millward, M., Amanuel, B., Ziman, M., Gray, E. (2019). Locus-specific concordance of genomic alterations between tissue and plasma circulating tumor DNA in metastatic melanoma. Molecular Oncology, 13(2), 171-184. https://doi.org/10.1002/1878-0261.12391.
  • Stark, M., Gray, E., Isaacs, T., Chen, F., Millward, M., McEvoy, A., Zaenker, P., Ziman, M., Soyer, H., Glasson, W., Warrier, S., Stark, A., Rolfe, O., Palmer, J., Hayward, N. (2019). A Panel of Circulating MicroRNAs Detects Uveal Melanoma With High Precision. Translational Vision Science and Technology, 8(6), Article 12. https://doi.org/10.1167/tvst.8.6.12.
  • McEvoy, A., Pereira, M., Reid, A., Pearce, R., Cowell, L., Al-Ogaili, Z., Khattak, A., Millward, M., Meniawy, T., Gray, E., Ziman, M. (2019). Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies. Oncotarget, 10(2), 113-122. https://doi.org/10.18632/oncotarget.26451.
  • Osborne, D., Domenico, J., Luo, Y., Reid, A., Amato, C., Zhai, Z., Gao, D., Ziman, M., Dinarello, C., Robinson, W., Fujita, M. (2019). Interleukin‐37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome. Molecular Carcinogenesis, 58(9), 1670-1679. https://doi.org/10.1002/mc.23044.

Journal Articles

  • Cruickshank, T., Reyes, A., Penailillo, L., Pulverenti, T., Bartlett, D., Zaenker, P., Blazevich, T., Newton, R., Thompson, J., Lo, J., Ziman, M. (2018). Effects of multidisciplinary therapy on physical function in Huntington’s disease. Acta Neurologica Scandinavica, 138(6), 500-507. https://doi.org/10.1111/ane.13002.
  • Zaenker, P., Lo, J., Pearce, R., Cantwell, P., Cowell, L., Lee, M., Quirk, C., Law, H., Gray, E., Ziman, M. (2018). A diagnostic autoantibody signature for primary cutaneous melanoma. Oncotarget, 9(55), 30539-30551. https://doi.org/10.18632/oncotarget.25669.
  • Beasley, A., Isaacs, T., Khattak, A., Freeman, J., Allcock, R., Chen, F., Pereira, M., Yau, K., Bentel, J., Vermeulen, T., Beasley, L., Millward, M., Ziman, M., Gray, E. (2018). Clinical Application of Circulating Tumor Cells and Circulating Tumor DNA in Uveal Melanoma. JCO Precision Oncology, 2(May 17, 2018), 12p.. https://doi.org/10.1200/PO.17.00279.
  • Marsavela, G., Aya-Bonilla, C., Warkiani, M., Gray, E., Ziman, M. (2018). Melanoma circulating tumor cells: Benefits and challenges required for clinical application. Cancer Letters, 424(Jun 2018), 1-8. https://doi.org/10.1016/j.canlet.2018.03.013.
  • Reyes, A., Salomonczyk, D., Teo, W., Medina, L., Bartlett, D., Pirogovsky-Turk, E., Zaenker, P., Bloom, J., Simmons, R., Ziman, M., Gilbert, P., Cruickshank, T. (2018). Computerised dynamic posturography in premanifest and manifest individuals with Huntington's disease. Scientific Reports, 8(1), Article number 14615. https://doi.org/10.1038/s41598-018-32924-y.
  • McEvoy, A., Wood, B., Ardakani, N., Pereira, M., Pearce, R., Cowell, L., Robinson, C., Grieu-Iacopetta, F., Spicer, A., Amanuel, B., Ziman, M., Gray, E. (2018). Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues: A Comparison with Sanger Sequencing and Pyrosequencing. The Journal of Molecular Diagnostics, 20(2), 240-252. https://doi.org/10.1016/j.jmoldx.2017.11.009.
  • Dunkel, Y., Reid, A., Ear, J., Aznar, N., Millward, M., Gray, E., Pearce, R., Ziman, M., Ghosh, P. (2018). Prognostic relevance of CCDC88C (Daple) transcripts in the peripheral blood of patients with cutaneous melanoma. Scientific Reports, 8(1), Article number 18036. https://doi.org/10.1038/s41598-018-36173-x.
  • McEvoy, A., Warburton, L., Al-Ogaili, Z., Celliers, L., Beasley, L., Pereira, M., Khattak, A., Meniawy, T., Millward, M., Ziman, M., Gray, E. (2018). Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients. BMC Cancer, 18(1), Article no. 726. https://doi.org/10.1186/s12885-018-4637-6.

Journal Articles

  • McEvoy, A., Beasley, L., Pereira, M., Giardina, T., Robinson, C., Khattak, M., Meniawy, T., Pritchard, A., Hayward, N., Amanuel, B., Millward, M., Ziman, M., Gray, E. (2017). Sensitive droplet digital PCR method for detection of TERT promoter mutations in cell free DNA from patients with metastatic melanoma. Oncotarget, 8(45), 78890-78900. https://doi.org/10.18632/oncotarget.20354.
  • Beasley, L., Warburton, L., Millward, M., Ziman, M., Gray, E. (2017). Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma. Cancer Letters, 404(28 Sept, 2017), 62-69. https://doi.org/10.1016/j.canlet.2017.06.030.
  • Beasley, L., Gray, E., Kurdykowski, S., David, A., Descargues, P., Ziman, M. (2017). SIRT1 activation mediates heat-induced survival of UVB damaged Keratinocytes. BMC Dermatology, 17(June 2017), Article No. 8. https://doi.org/10.1186/s12895-017-0060-y.
  • Aya-Bonilla, C., Marsavela, G., Freeman, J., Lomma, C., Frank, M., Khattak, M., Tarek, M., Millward, M., Warkiani, M., Gray, E., Ziman, M. (2017). Isolation and detection of circulating tumour cells from metastatic melanoma patients using a slanted spiral microfluidic device. Oncotarget, 8(40), 67355-67368. https://doi.org/10.18632/oncotarget.18641.
  • Dejong, H., Abbott, S., Zelesco, M., Kennedy, B., Ziman, M., Wood, F. (2017). The validity and reliability of using ultrasound elastography to measure cutaneous stiffness, a systematic review. International Journal of Burns and Trauma, 7(7), 124-141.

Journal Articles

  • Beasley, L., Gray, E., Kurdykowski, S., David, A., Hart, P., Descargues, P., Ziman, M. (2016). Heat-mediated reduction of apoptosis in UVB-damaged keratinocytes in vitro and in human skin ex vivo. BMC Dermatology, 16(1), Article no. 6. https://doi.org/10.1186/s12895-016-0043-4.
  • Zaenker, P., Gray, E., Ziman, M. (2016). Autoantibody Production in Cancer—The Humoral Immune Response toward Autologous Antigens in Cancer Patients. Autoimmunity Reviews, 15(5), 477-483. https://doi.org/10.1016/j.autrev.2016.01.017.
  • Phan, T., Carter, O., Adams, C., Waterer, G., Chung, L., Hawkins, M., Rudd, C., Ziman, M., Strobel, N. (2016). Discriminant validity of the Hospital Anxiety and Depression Scale, Beck Depression Inventory (II) and Beck Anxiety Inventory to confirmed clinical diagnosis of depression and anxiety in patients with chronic obstructive pulmonary disease. Chronic Respiratory Disease, 13(3), 220-228. https://doi.org/10.1177/1479972316634604.
  • Bartlett, D., Cruickshank, T., Hannan, A., Eastwood, P., Lazar, A., Ziman, M. (2016). Neuroendocrine and neurotrophic signaling in Huntington's Disease: Implications for pathogenic mechanisms and treatment strategies. Neuroscience and Biobehavioral Reviews, 71(2016), 444-454. https://doi.org/10.1016/j.neubiorev.2016.09.006.

Book Chapters

Journal Articles

  • Bartlett, D., Boyle, GM., Ziman, M., Medic, S. (2015). Mechanisms contributing to differential regulation of PAX3 downstream target genes in normal human epidermal melanocytes versus melanoma cells. PLoS One, 10(4), Article no. e0124154. https://doi.org/10.1371/journal.pone.0124154.
  • Cruickshank, T., Reyes, A., Ziman, M. (2015). A systematic review and meta-analysis of strength training in individuals with Multiple Sclerosis or Parkinson disease. Medicine, 94(4), e411. https://doi.org/10.1097/MD.0000000000000411.
  • Cruickshank, T., Thompson, J., Domínguez , J., Reyes, A., Bynevelt, M., Georgiou-Karistianis, N., Barker, R., Ziman, M. (2015). The effect of multidisciplinary rehabilitation on brain structure and cognition in Huntington's disease: an exploratory study. Brain and Behavior, 5(2), 1-10. https://doi.org/10.1002/brb3.312.
  • Reid, A., Freeman, J., Millward, M., Ziman, M., Gray, E. (2015). Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR. Clinical Biochemistry, 48(15), 999-1002. https://doi.org/10.1016/j.clinbiochem.2014.12.007.
  • Gray, E., Reid, A., Bowyer, S., Beasley, L., Siew, K., Pearce, R., Cowell, L., Frank, M., Millward, M., Ziman, M. (2015). Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment. Journal of Investigative Dermatology, 135(8), 2040-2048. https://doi.org/10.1038/jid.2015.127.
  • Reyes, A., Cruickshank, T., Nosaka, K., Ziman, M. (2015). Respiratory muscle training on pulmonary and swallowing function in patients with Huntington's disease: A pilot randomised controlled trial. Clinical Rehabilitation, 29(10), 961-973. https://doi.org/10.1177/0269215514564087.
  • Collins, L., Begeti, F., Panin, F., Lazar, A., Cruickshank, T., Ziman, M., Mason, S., Barker, R. (2015). Novel Nut and Bolt Task Quantifies Motor Deficits in Premanifest and Manifest Huntington’s Disease. PLoS Currents, 7(Huntington Disease), online. https://doi.org/10.1371/currents.hd.ded251617ae62a1364506b0521bd3761.
  • Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Siew, K., Lomma, C., Cooper, A., Khattak, M., Meniawy, T., Long, G., Carlino, M., Millward, M., Ziman, M. (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018. https://doi.org/10.18632/oncotarget.5788.

Conference Publications

  • Maurya, D., Fooladvand, M., Gray, E., Ziman, M., Alameh, K. (2015). Lab-on-chip platform for circulating tumor cells isolation. Micro+Nano Materials, Devices, and Systems (9668-34). SPIE. https://doi.org/10.1117/12.2201127.

Journal Articles

  • Cruickshank, T., Reyes, A., Penailillo, L., Thompson, J., Ziman, M. (2014). Factors that contribute to balance and mobility impairments in individuals with Huntington's disease. Basal Ganglia, 4(2), 67-70. https://doi.org/10.1016/j.baga.2014.04.002.
  • Fyfe, G., Fyfe, S., Meyer, J., Ziman, M., Sanders, K., Hill, J. (2014). Students reflecting on test performance and feedback: An on-line approach. Assessment and Evaluation in Higher Education, 39(2), 179-194. https://doi.org/10.1080/02602938.2013.801063.
  • Blake, J., Ziman, M. (2014). Pax genes: regulators of lineage specification and progenitor cell maintenance. Development, 141(4), 737-751. https://doi.org/10.1242/dev.091785.
  • Reyes, A., Cruickshank, T., Thompson, J., Ziman, M., Nosaka, K. (2014). Surface electromyography activity of submental muscles during swallowing and expiratory muscle training tasks of Huntington’s disease patients. Journal of Electromyography and Kinesiology, 24(1), 153-158. https://doi.org/10.1016/j.jelekin.2013.09.009.
  • Klinac, D., Gray, E., Freeman, J., Reid, A., Bowyer, S., Millward, M., Ziman, M. (2014). Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer, 14(1), Article number 423. https://doi.org/10.1186/1471-2407-14-423.
  • Reyes, A., Cruickshank, T., Ziman, M., Nosaka, K. (2014). Pulmonary function in patients with Huntington's Disease. BMC Pulmonary Medicine, 14(2014), Article No. 89. https://doi.org/10.1186/1471-2466-14-89.

Journal Articles

  • Beasley, L., Gray, E., Ziman, M. (2013). Heat stress: a risk factor for skin carcinogenesis. Cancer Letters, 337(1), 35-40. https://doi.org/10.1016/j.canlet.2013.05.039.
  • Thompson, J., Cruickshank, T., Penailillo, L., Lee, J., Newton, R., Barker, R., Ziman, M. (2013). The effects of multidisciplinary rehabilitation in patients with early-to-middle-stage Huntington's disease: a pilot study.. European Journal of Neurology, 20(9), 1325-1329. https://doi.org/10.1111/ene.12053.
  • Dye, DE., Medic, S., Ziman, M., Coombe, DR. (2013). Melanoma Biomolecules: Independently Identified but Functionally Intertwined. Frontiers in Oncology, 3 Sep(2013), Article No 252. https://doi.org/10.3389/fonc.2013.00252.
  • Blake, J., Ziman, M. (2013). The Characterisation of Pax3 Expressant Cells in Adult Peripheral Nerve.. PLoS One, 8(3), e59184. https://doi.org/10.1371/journal.pone.0059184.
  • Zaenker, P., Ziman, M. (2013). Serological Autoantibodies as Diagnostic Cancer Biomarkers - A Review. Cancer Epidemiology Biomarkers and Prevention, 22(12), 2161-81. https://doi.org/10.1158/1055-9965.EPI-13-0621.
  • Klinac, D., Gray, E., Milward, M., Ziman, M. (2013). Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring. Frontiers in Oncology, 3(March 2013), Article 00054. https://doi.org/10.3389/fonc.2013.00054.
  • Reyes, A., Ziman, M., Nosaka, K. (2013). Respiratory muscle training for respiratory deficits in neurodegenerative disorders: a systematic review. Chest, 143(5), 1386-1394. https://doi.org/10.1378/chest.12-1442.
  • Reid, A., Millward, M., Pearce, R., Lee, M., Frank, M., Ireland, A., Monshizadeh, L., Rai, T., Heenan, P., Medic, S., Kumarasinghe, P., Ziman, M. (2013). Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression. British Journal of Dermatology, 168(1), 85-92. https://doi.org/10.1111/bjd.12057.

Book Chapters

  • Ziman, M., Millward, M., Pearce, R., Lee, M. (2012). Serological Biomarkers in Melanoma. Diagnostic and Prognostic Biomarkers and Therapeutic Targets in Melanoma (195-208). Humana Press. https://doi.org/10.1007/978-1-60761-433-3_15.

Journal Articles

  • Charytonowicz, E., Matushansky, I., Castillo-Martin, M., Ladanyi, M., Cordon-Cardo, C., Domingo-Domenech, J., Ziman, M. (2012). PAX7-FKHR fusion gene inhibits myogenic differentiation via NF-kappaB upregulation.. Clinical and Translational Oncology, 14(3), 197-206. https://doi.org/10.1007/s12094-012-0784-4.
  • Freeman, J., Gray, E., Milward, M., Pearce, R., Ziman, M. (2012). Evaluation of a multi-marker immunomagnetic enrichment assay for the quantification of circulating melanoma cells. Journal of Translational Medicine, 10(1), art. no. 192. https://doi.org/10.1186/1479-5876-10-192.

Journal Articles

  • Thompson, J., Ziman, M. (2011). Pax genes during neural development and their potential role in neuroregeneration. Progress in Neurobiology, 95(3), 334-351. https://doi.org/10.1016/j.pneurobio.2011.08.012.
  • Ireland, A., Millward, M., Pearce, R., Lee, M., Ziman, M. (2011). Genetic factors in metastatic progression of cutaneous melanoma: The future role of circulating melanoma cells in prognosis and management. Clinical and Experimental Metastasis, 28(4), 327-336. https://doi.org/10.1007/s10585-010-9368-2.
  • Medic, S., Rizos, H., Ziman, M. (2011). Differential PAX3 functions in normal skin melanocytes and melanoma cells. Biochemical and Biophysical Research Communications, 411(4), 832-837. https://doi.org/10.1016/j.bbrc.2011.07.053.
  • Johnston, S., Wilkes, G., Thompson, J., Ziman, M., Brightwell, R. (2011). Inhaled methoxyflurane and intranasal fentanyl for prehospital management of visceral pain in an Australian ambulance service.. Emergency Medicine Journal, 28(1), 57-63. https://doi.org/10.1136/emj.2009.078717.
  • Thomas, M., Stone, L., Evill, L., Ong, S., Ziman, M., Hool, L. (2011). Bone marrow stromal cells as replacement cells for Parkinson's disease: generation of an anatomical but not functional neuronal phenotype.. Translational Research: the journal of laboratory and clinical medicine, 157(2), 56-63. https://doi.org/10.1016/j.trsl.2010.11.001.
  • Charytonowicz, E., Matushansky, I., Castillo-Martin, M., Hricik, T., Cordon-Cardo, C., Ziman, M. (2011). Alternate PAX3 and PAX7 C-terminal isoforms in myogenic differentiation and sarcomagenesis. Clinical and Translational Oncology, 13(3), 194-203. https://doi.org/10.1007/s12094-011-0640-y.

Journal Articles

Journal Articles

  • Charytonowicz, E., Cordon-Cardo, C., Matushansky, I., Ziman, M. (2009). Alveolar rhabdomyosarcoma: Is the cell of origin a mesenchymal stem cell?. Cancer Letters, 279(2), 126–136. https://doi.org/10.1016/j.canlet.2008.09.039.
  • Medic, S., Ziman, M. (2009). PAX3 across the spectrum: from melanoblast to melanoma. Critical Reviews in Biochemistry and Molecular Biology, 44(2-3), 85-97.
  • Thomas, M., Tyers, P., Lazic, S., Barker, R., Beazley, L., Ziman, M. (2009). Graft outcomes influenced by co-expression of Pax7 in graft and host tissue. Journal of Anatomy, 214(3), 396-405.

Journal Articles

  • White, R., Ziman, M. (2008). Genome-wide discovery of Pax7 target genes during development. Physiological Genomics, 33(1), 41-49.
  • Thompson, J., Zembrzycki, A., Mansouri, A., Ziman, M. (2008). Pax7 is requisite for maintenance of a subpopulation of superior collicular neurons and shows a diverging expression pattern to Pax3 during superioir collicular development. BMC Developmental Biology, 8(30-May-2008), 62-72. https://doi.org/10.1186/1471-213X-8-62.
  • Blake, J., Thomas, M., Thompson, J., White, R., Ziman, M. (2008). Perplexing Pax: From Puzzle to Paradigm. Developmental Dynamics, 237(10), 2791-2803. https://doi.org/10.1002/dvdy.21711.

Journal Articles

  • Medic, S., Pearce, R., Heenan, P., Ziman, M. (2007). Molecular Markers of Circulating Melanoma Cells. Pigment Cell Research, 20(2), 80-91.
  • Michaelsky, K., Ziman, M. (2007). Current Concepts In Human Prion Protein (Prp) Misfolding, Prnp Gene Polymorphisms And Their Contribution To Creutzfeldt-Jakob Disease (CJD).. Histology and Histopathology, 22(10), 1149-1159.
  • Thompson, J., Lovicu, F., Ziman, M. (2007). Pax7 and superior collicular polarity: insights from Pax6 (Sey) mutant mice. Experimental Brain Research, 178(3), 316-325.
  • Mitchell, M., Tabarini, D., Ziman, M. (2007). Single Nucleotide Polymorphisms Present in the Fusion Gene the Intronic Cis Regulatory Regions of PAX7: A Potential Linkage to Increased Tumorigenesis of Rhabdomyosarcoma Elucidated via In Silico Biol. European Journal of Scientific Research, 16(2), 290-302.
  • Thomas, M., Barker, R., Beazley, L., Ziman, M. (2007). Pax7 expression in the adult rat superior colliculus following optic nerve injury. Neuroreport, 18(2), 105-109.

Conference Publications

  • Ziman, M., Fyfe, G., Fyfe, S., Meyer, J., Plastow, K. (2007). Increased participation by university students in external paid employment fuels the need for flexibility in online delivery. Conference Proceedings Cape Town South Africa 2-5 December 2007 5th International Conference on Researching Work and Learning (RWL5) (905-911). Division for Lifelong Learning.
  • Meyer, J., Fyfe, S., Fyfe, G., Ziman, M., Plastow, K., Sanders, K., Hill, J. (2007). An articulated approach to the development and evaluation of automated feedack for online MCQ quizzes in Human Biology. Symposium Proceedings Science Teaching and Learning Research including Threshold Concepts September 27 & 28, 2007 The University of Sydney (52-57). University of Sydney.
  • Ziman, M., Meyer, J., Plastow, K., Fyfe, G., Fyfe, S., Sanders, K., Hill, J., Brightwell, R. (2007). Student optimism and appreciation of feedback. Student Engagement. Proceedings of the 16th Annual Teaching Learning Forum, 30-31 January 2007. Perth: The University of Western Australia (1-15). UWA.

Book Chapters

  • Ziman, M., White, R. (2006). PAX genes in cell differentiation, lineage development and pathogenesis. The Molecular and Cellular Pathology of Cancer Progression and Prognosis (235-259). Research Signpost.

Journal Articles

  • Rodger, J., King, CE., Lukehurst, S., Chen, P., Dunlop, SA., Beazley, LD., Ziman, M. (2006). Changing Pax6 expression correlates with axon outgrowth and restoration of topography during optic nerve regeneration. Neuroscience, 142(4), 1043-1054.
  • Mitchell, M., Tabarini, D., Ziman, M. (2006). Loss of Heterozygosity Analysis at selected Single Nucleotide Polymorphism Sites in the Intronic Regions of PAX7 via In Silico biology and Microsatelite Analysis. Journal of American Science, 2(4), 18-33.
  • Johnston, S., Brightwell, R., Ziman, M. (2006). Paramedics and pre-hospital management of acute myocardial infarction: diagnosis and reperfusion. Emergency Medicine Journal, 23(5), 331-334.
  • White, R., Ziman, M. (2006). A comparative analysis of shotgun-cloning and tagged-random amplification-cloning of chromatin immunoprecipitation-isolated genome fragments. Biochemical and Biophysical Research Communications, 346(2), 479-483.
  • Mitchell, M., Ziman, M. (2006). An In Silico Investigation into the Discovery of Novel Cis-acting Elements within the Intronic Regions of Human PAX7. Nature and Science, 4(3), 69-85.
  • Thomas, M., Beazley, LD., Ziman, M. (2006). A multiphasic role for Pax7 in tectal development. Experimental Brain Research, 169(2), 266-271.

Conference Publications

  • Fyfe, G., Fyfe, S., Hill, J., Meyer, J., Plastow, K., Sanders, K., Ziman, M. (2006). With Age and experience comes an appreciation of the value of feedback for learning. Enhancing Student Learning; 2006 Evaluations and Assessment Conference Refereed Papers (39-47). Learning Support Network, Curtin University of Technology.

Journal Articles

  • Blake, J., Ziman, M. (2005). Pax3 transcripts in melanoblast development. Development Growth and Differentiation, 47(9), 627-635.
  • Michalczyk, K., Ziman, M. (2005). Nestin structure and predicted function in cellular cytoskeletal organisation. Histology and Histopathology, 20(1), 665-671.
  • White, R., Lamey, T., Ziman, M., Koenders, A. (2005). Isolation and expression analysis of a Pax group III gene from the crustacean Cherax destructor. Development Genes and Evolution, 215(6), 306-312.

Journal Articles

  • Thompson, J., Lovicu, F., Ziman, M. (2004). The Role of Pax7 in determining the cytoarchitecture of the superior colliculus. Development Growth and Differentation, 46(n/a), 213-218.
  • Thomas, M., Lazic, S., Beazley, LD., Ziman, M. (2004). Expression profiles suggest a role for Pax7 in the establishment of tectal polarity and map refinement. Experimental Brain Research, 156(n/a), 263-273.
  • Lamey, T., Koenders, A., Ziman, M. (2004). Pax genes in myogenesis: Alternate transcripts add complexity. Histology and Histopathology, 19(4), 1289-1300.

Conference Publications

  • Ziman, M. (2004). Research and teaching nexus: Vital for teaching and learning of genetics. EDU-COM International Conference Proceedings (447-455). Edith Cowan University.
  • Pratt, A., Ziman, M., Leggett, M., McDermid, D. (2004). Expanding horizons: Student Views on internationalisation of the curriculum. EDU-COM 2004 International Conference Proceedings (304-314). Edith Cowan University.

Journal Articles

  • Ziman, M., Rodger, J., Lukehurst, S., Hancock, D., Dunlop, SA., Beazley, LD. (2003). A dorso-ventral gradient of Pax6 in the developing retina suggests a role in topographic map formation. Developmental Brain Research, 140(2), 299-302.
  • Blake, J., Ziman, M. (2003). Aberrant PAX3 and PAX7 expression. A link to the metastatic potential of embryonal rhabdomyosarcoma and cutaneous malignant melanoma?. Histology and Histopathology, 18(2), 529-539.

Conference Publications

  • Ziman, M. (2003). In-class conference provides and authentic learning experience. Improving learning outcomes through flexible science teaching. (8 pages). Carfax Publishing, Taylor and Francis Ltd.

Research Projects

  • Enabling Advanced Single Cell Cancer Genomics in Western Australia, Cancer Research Trust, The Grant, 2017 ‑ 2026, $615,245.
  • The effect of cognitive and exercise training on Brain Atrophy and Cognitive Decline in Breast Cancer Patients Treated with Adjuvant Chemotherapy Agents, Cancer Council of WA Inc, Collaborative Cancer Grant Scheme, 2018 ‑ 2025, $49,966.
  • The development and evaluation of a novel multidisciplinary therapy coaching program for people with mild-to-moderate Huntington’s disease. , Perpetual Ltd, IMPACT Philanthropy Application Program, 2018 ‑ 2024, $299,888.
  • Circulating Melanoma Cells as Predictive Biomarkers of Response to Immune Checkpoint Blockade , Cancer Council of WA Inc, Grant, 2020 ‑ 2022, $100,000.
  • Medical and Health Research Infrastructure Fund 2019 (Round 23), Department of Health WA, Medical and Health Research Infrastructure, 2020 ‑ 2021, $17,743.
  • Liquid biopsy for personalised monitoring of melanoma patients , National Health and Medical Research Council, Development Grants, 2017 ‑ 2020, $820,889.
  • Medical and Health Research Infrastructure Fund 2018 (Round 22), Department of Health WA, Medical and Health Research Infrastructure, 2019 ‑ 2020, $17,691.
  • Early Detection of Cancer Spread and Treatment of Ocular Melanoma, Cancer Council of WA Inc, PhD Top Up Scholarship, 2018 ‑ 2020, $30,000.
  • Translation of "Liquid Biopsy" Research into Clinical Practice, Western Australian Health Translation Network, Early Career Fellowships, 2019 ‑ 2020, $121,074.
  • Single Cell Whole Transcriptome Sequencing of Melanoma Circulating Tumour Cells (CTCs): Unveiling Cell Diversity, Tour de Cure, Pioneering Cancer Research Grant, 2019, $120,000.
  • Predictive significance of circulating tumour cells (CTCs), circulating tumour DNA (ctDNA) and serum vascular endothelial growth factor (VEGF) in advanced melanoma patients treated with pembrolizumab, Merck Sharp and Dohme (Australia) Pty Ltd, Grant, 2016 ‑ 2019, $73,300.
  • A liquid biopsy to assist with staging of melanoma patients, Perpetual Ltd, IMPACT Philanthropy Application Program, 2017 ‑ 2019, $134,161.
  • High-frequency ultrasound and photoacoustic imaging for Western Australia, Australian Research Council, Grant - Linkage (Infrastructure), 2018 ‑ 2019, $621,198.
  • Medical and Health Research Infrastructure Fund 2017 (Round 21), Department of Health WA, Medical and Health Research Infrastructure, 2018 ‑ 2019, $14,816.
  • Development of a Multiplex Test for the Early Diagnosis of Melanoma, Tour de Cure, Senior Research Grant, 2019, $280,000.
  • Circulating Tumour DNA to Predict and Monitor Treatment Response and Detect Acquired Resistance in Patients with Metastatic Melanoma, Ramaciotti Foundation, Grant, 2015 ‑ 2018, $99,911.
  • Genetic Analysis of Blood Markers for Prognosis in Patients with Uveal Melanoma, University of Western Australia, Raine Foundation Grant, 2016 ‑ 2018, $100,000.
  • Blood Based Biomarkers Predictive of Treatment Response in Melanoma, Cancer Council of WA Inc, Grant, 2016 ‑ 2018, $246,822.
  • Liquid Biopsy for Prognosis of Uveal Melanoma, The Ophthalmic Research Institute of Australia, ORIA - Grant, 2018, $27,551.
  • Medical and Health Research Infrastructure Fund 2016 (Round 20), Department of Health WA, Medical and Health Research Infrastructure, 2017 ‑ 2018, $13,910.
  • Translation of the HEROs Program of Multidisciplinary Therapy for Patients with Huntington s Disease (HD) into community settings, Edith Cowan University, ECU Industry Collaboration Scheme - 2016 Open Round, 2017 ‑ 2018, $75,423.
  • Blood based biomarkers predictive of treatment efficacy in metastatic melanoma, Spinnaker Health Research Foundation, Collaborative Research Partnership Grants, 2017 ‑ 2018, $107,448.
  • Understanding the Role of Melanoma Exosomes in Intercellular Communication, Cancer Council of WA Inc, Collaborative Cancer Grant Scheme, 2017 ‑ 2018, $43,230.
  • A Blood Based ‘Liquid Biopsy’ to Improve Healthcare for Metastatic Melanoma Patients, Department of Health WA, SHRAC Research Translation Projects, 2016 ‑ 2018, $218,693.
  • Western Australia Single-Cell Isolation and Genomics Preparation Facility, Australian Research Council, Grant - Linkage (Infrastructure), 2017, $430,000.
  • A preliminary study investigating blood markers of response to treatment with immune system targeted therapy in advanced melanoma, Cancer Council of WA Inc, Grant - Early Career Investigator, 2015 ‑ 2017, $35,000.
  • Circulating Tumour Cells (CTCs) as biomarkers in metastatic melanoma, Edith Cowan University, ECU Early Career Researcher Grant - 2016, 2016 ‑ 2017, $30,000.
  • Gene expression profiling of circulating tumour cells (CTCs) isolated from metastatic melanoma patients using a microfluidic chip, Cancer Council of WA Inc, Grant - Early Career Investigator, 2016 ‑ 2017, $35,000.
  • Medical and Health Research Infrastructure Fund (MHRIF) 2015 (Round 19), Department of Health WA, Medical and Health Research Infrastructure, 2016 ‑ 2017, $18,590.
  • Circulating Melanoma Cells as Predictive Biomarkers of Treatment Response and Disease Status, Cancer Council of WA Inc, Grant, 2015 ‑ 2017, $111,519.
  • The effect of multidisciplinary therapy on neurodegeneration and clinical decline in Huntington’s disease individuals before the onset of diagnosable symptoms., Edith Cowan University, ECU Early Career Researcher Grant - 2016, 2016 ‑ 2017, $27,900.
  • HEROs Huntington's disease Exercise Rehabilitation Optimisation Study, Lotterywest, Grant, 2014 ‑ 2017, $560,011.
  • Using a Functional Protein Array to Identify Autoantibody Biomarkers with Diagnostic Potential for Melanoma, National Health and Medical Research Council, Development Grants, 2014 ‑ 2017, $452,058.
  • Transcriptomic profiling of Circulating Tumour Cells (CTCs) isolated from metastatic melanoma patients, Edith Cowan University, School of Medical and Health Sciences Research Grant Scheme 2016, 2016, $10,000.
  • A Single-Molecule Super-Resolution Microscopy Facility in Western Australia, Australian Research Council, Grant - Linkage (Infrastructure), 2016, $1,600,000.
  • 2015 NHMRC Equipment Grant, National Health and Medical Research Council, Equipment Grant 2015, 2015 ‑ 2016, $6,798.
  • Mass Cytometry: A breakthrough in multidimensional systems biology, Australian Research Council, Grant - Linkage (Infrastructure), 2015 ‑ 2016, $1,081,489.
  • Circulating Tumour Cells (CTCs) as a diagnostic tool to monitor disease progression in melanoma patients, Edith Cowan University, ECU Industry Collaboration Grant - 2015 (Round 1), 2015 ‑ 2016, $25,000.
  • PAX3 dysregulation in glioblastoma., Edith Cowan University, ECU Early Career Researcher Grant - 2015, 2015 ‑ 2016, $22,800.
  • Melanoma Mutation Profiling For Personalised Treatment, National Health and Medical Research Council, Project Grants, 2013 ‑ 2016, $765,359.
  • The role of DACH1 and the mir-200 family in medulloblastoma pathogenesis, Cancer Council of WA Inc, Cancer Council, Scholarship, 2014 ‑ 2015, $2,000.
  • In-Vivo Multispectral and X-Ray Micro-CT Imaging: Founding a Western Australian Small Animal Imaging Core Facility, Australian Research Council, Grant - Linkage (Infrastructure), 2010 ‑ 2015, $804,000.
  • 2014 NHMRC Equipment Grant Rob Newton and Mel Ziman, National Health and Medical Research Council, Equipment Grant 2014, 2014 ‑ 2015, $9,336.
  • The Transcriptional profile of a metastatic circulation melanoma cell, National Health and Medical Research Council, Project Grants, 2011 ‑ 2014, $264,182.
  • Detection of Vemurafenib Resistance in Circulating Tumour Cells for Personalised Treatment of Melanoma, Harry Perkins Institute of Medical Research, Scott Kirkbride Melanoma Research Centre - Discovery Research Priming Grant, 2013 ‑ 2014, $68,182.
  • PAX3-mediated melanocytic response to environmental factors, Edith Cowan University, ECU Early Career Researcher Grant - 2013, 2013 ‑ 2014, $25,000.
  • Genetic Analysis of Melanoma Cells in Blood For Personalised Treatment Management, Edith Cowan University, ECU Early Career Researcher Grant - 2013, 2013 ‑ 2014, $24,083.
  • Standard Equipment Grant 2012, National Health and Medical Research Council, Equipment Grant 2012, 2012 ‑ 2014, $5,744.
  • The role of DACH1 and the mir-200 family in medulloblastoma pathogenesis, Telethon Kids Institute, Honours Telethon Adventurers Children's Brain Cancer Training Award, 2014, $4,000.
  • The effects of environmental enrichment on physiological markers of disease progression in patients with Huntington’s disease., Edith Cowan University, ECU Early Career Researcher Grant - 2012 (Round 1), 2012 ‑ 2013, $24,568.
  • The Effects of Environmental Enrichment on Clinical Measures of Disease Progression and Quality of Life for Patients with Huntington's Disease, Huntington's WA (Inc), Lotterywest Grant, 2010 ‑ 2013, $393,317.
  • Detection of stem cell markers expression in circulating melanoma cells using multiparameter flow cytometry as a prognosis tool, Edith Cowan University, ECU Early Career Researcher Grant - 2012 (Round 1), 2012 ‑ 2013, $19,480.
  • Expanding Capacity and Capability in Western Australian Flow Cytometry for Earth, Oceans, Environmental and Biomedical Science: State-of-the-Art Four Laser and 12 Colour Analysis, Australian Research Council, Grant - Linkage (Infrastructure), 2012 ‑ 2013, $295,000.
  • Nano mechanical analysis of metastactic melanoma cancer cells using atomic force microscopy, Cancer Council of WA Inc, Cancer Council, Scholarship, 2012, $7,500.
  • A high-throughput protein production and structure facility, Australian Research Council, Grant - Linkage (Infrastructure), 2012, $470,000.
  • The association between environmental stresses (UV, heat and chemicals) and melanoma incidence amongst staff at Telfer Gold Mine, Edith Cowan University, ECU Industry Collaboration - Grant, 2011 ‑ 2012, $37,500.
  • Neon Transfection System and Biomedical Research Grade -30oC Freezer for Alzheimer’s and Melanoma Research, National Health and Medical Research Council, Equipment Grant 2011, 2011 ‑ 2012, $10,927.
  • CCD Camera for Inverted Fluorescent Microscope in Alzheimer's and Melanoma Research, National Health and Medical Research Council, Equipment Grant, 2010 ‑ 2011, $10,881.
  • Nature's Wonder, Cocky Smart, Grant, 2010 ‑ 2011, $125,023.
  • The Use of Circulating Melanoma Cells to monitor Treatment Efficacy in Patients with Cutaneous Malignant Melanoma, University of Western Australia, Grant - CaPCREU, 2010 ‑ 2011, $17,240.
  • Evaluation of Paramedic Treatment Techniques to Assess Contributing Factors to Mortality in the Pre Hospital Management of Traumatic Brain Injury, Edith Cowan University, ECU Industry Collaboration - Grant, 2009 ‑ 2011, $47,600.
  • Patient outcome affected by paramedic pre hospital treatment of patients with severe brain injuries, Edith Cowan University, ECU Industry Collaboration - Grant, 2007 ‑ 2011, $62,569.
  • Characterisation and Quantification of Circulating Melanoma Cells, Cancer Council of WA Inc, Cancer Council, Scholarship, 2010, $3,000.
  • Detection and Characterisation of Circulating Cutaneous Malignant Melanoma Cells, Edith Cowan University, ECU Industry Collaboration - Grant, 2009 ‑ 2010, $30,004.
  • Isolation and Characterisation of Melanoma Cancer Stem Cells, Edith Cowan University, ECU Early Career Researcher - Grant, 2008 ‑ 2010, $24,975.
  • A Western Australian Core Cell Sorting Facility - Ultra-Small Objects and Rare Cell Populations, Australian Research Council, Grant - Linkage (Infrastructure), 2009 ‑ 2010, $524,000.
  • Neurological cell replacement therapies: improving outcomes by matching developmental profiles of transplanted cells with the damaged brain area. , Australian Research Council, Grant - Discovery Projects, 2007 ‑ 2010, $118,176.
  • Quantification and Characterisation of Circulating Cutaneous Malignant Melanoma Cells, Cancer Council of WA Inc, Grant, 2009, $70,000.
  • Development of a Blood Test for Cutaneous Malignant Melanoma, Edith Cowan University Foundation, Donation, 2007 ‑ 2008, $34,485.
  • A cryopreparation facility for Western Australia, Australian Research Council, Grant - Linkage (Infrastructure), 2008, $410,000.
  • Development of a blood test for Cutaneous Malignant Melanoma, Edith Cowan University, ECU Industry Collaboration - Grant, 2007 ‑ 2008, $31,193.
  • Developmental genes and Melanoma detection, Edith Cowan University, ECU Industry Collaboration - Grant, 2005 ‑ 2008, $38,000.
  • Detection of Migrating Melanoma Cells in Peripheral Blood of Patients with Metastatic Melanoma, Cancer Council of WA Inc, Grant, 2007 ‑ 2008, $2,000.
  • Matching the developmental transcription factor profiles of transplanted cells and host injured brain regions is crucial for successful cell transplant therapies, Harry Perkins Institute of Medical Research, Grant, 2005 ‑ 2006, $60,000.
  • Corbett Research 'RotorGene' 2 channel real-time DNA multiplexing system, Ramaciotti Foundation, Grant, 2004 ‑ 2005, $49,000.

Research Student Supervision

No data available

Principal Supervisor

  • Master of Science (Human Biology), Pax3 and cutaneous malignant melanoma
  • Master of Science (Human Biology), Pax3 and cutaneous malignant melanoma
  • Doctor of Philosophy, The clinical utility of multidisciplinary rehabilitation in individuals with huntington's disease
  • Master of Science (Human Biology), The role of PAX3 in the metastasis of cutaneous malignant melanoma.
  • Master of Science (Human Biology), The identification of diagnostic serological autoantibodies for cutaneous melanoma.
  • Doctor of Philosophy, The role of PAX3/PAX7-fkhr in mesenchymal stem cell myogenic differentiation and rhabdomyosarcomagenesis.
  • Doctor of Philosophy, The identification and validation of a diagnostic signature of tumour-associated autoantibodies for the early diagnosis of cutaneous melanoma
  • Doctor of Philosophy, An investigation of the mechanism of PAX7 mediated oncogenesis via in silico biology.
  • Doctor of Philosophy, The utility of multidisciplinary rehabilitation as a treatment strategy for circadian rhythm and sleep disturbances in premanifest huntington's disease
  • Doctor of Philosophy, The developmental function of pax 7: Chromatin-immunoprecipitation discovery of PAX7 target genes
  • Doctor of Philosophy, Mechanobiology of scarring: Quantifying the mechanical properties of scar-tissue using shear-wave elastography
  • Master of Science (Human Biology), The efficacy of inhaled methoxyflurance and intranasal fentanyl for the pre hospital management of cardiac or visceral pain.
  • Doctor of Philosophy, Pulmonary and swallowing function in patients with huntington's disease.
  • Doctor of Philosophy, Breathing new life: Investigating ways to improve the mental health of people living with chronic obstructive pulmonary disease in wester Australia
  • Doctor of Philosophy, New perspectives on melanoma: The role of PAX3
  • Doctor of Philosophy, New perspectives on melanoma: The role of PAX3
  • Doctor of Philosophy, The role of PAX7 in the formation of the superior colliculus and the vertebrate visual system.
  • Doctor of Philosophy: The role of PAX3 and PAX7 in alveolar rhabdomyosarcoma focusing on DNA binding domains, alternative splicing and target gene analysis by microarray
  • Doctor of Philosophy: A possible role for PAX7 in initiating differentiation of neuronal cells in the optic tectum during normal development and after injury
  • Master of Science (Human Biology), Molecular genetic investigation of autosomal dominant hemifacial microsomia.
  • Master of Science (Human Biology), Optimisation of the isolation and identification of circulating melanoma cells
  • Doctor of Philosophy, Circulating tumour DNA: A non-invasive biomarker for melanoma
  • Master of Science (Human Biology), Pax3 expression, protein modifications and downstream target gene profiling in melanocytes and melanoma cells
  • Master of Science (Human Biology), The effectiveness of airway management in the pre hospital treatment of traumatic brain injury
  • Doctor of Philosophy, The characterisation of PAX3 expressant cells in adult peripheral nerve
  • Doctor of Philosophy, Heat stress: A risk factor for skin carcinogenesis

Co-principal Supervisor

  • Master of Science (Human Biology), The evaluation of Midazolam on head injured patients in the prehospital setting
  • Master of Science (Human Biology), Genetic markers in circulating tumour cells as a measure of the metastatic propensity of uveal melanoma

Associate Supervisor

  • Doctor of Philosophy, An investigation on role of the ATP-binding cassette B5 (ABCB5) transporter as potential mediator of melanoma resistance to BRAF inhibition
  • Master of Science (Medical Science), Characterizing PD-L1 expression in circulating melanoma and non-small cell lung cancer cells
  • Doctor of Philosophy, Assessment of the clinical utility of ctDNA analysis for melanoma management
Skip to top of page